Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news Viva Money extends operations to Maharashtra with innovative financial services In a strategic move to broaden its footprint in India, Viva Money, a subsidiary of Cyprus-based Tirona Limited,… byPallavi MadhirajuJune 17, 2024